Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q32 Bio ( (QTTB) ) has issued an update.
On February 17, 2026, Q32 Bio Inc. announced it had entered a definitive agreement with institutional investors for a $10.5 million registered direct offering of 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 additional shares, priced in line with its recent Nasdaq closing. The transaction, led by a new institutional investor with participation from an existing public institutional holder, is expected to close on or about February 18, 2026, with proceeds earmarked for working capital and to support research, clinical development and commercialization activities, including advancing bempikibart into future alopecia areata trials, bolstering Q32 Bio’s funding base as it progresses its autoimmune pipeline.
The most recent analyst rating on (QTTB) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Q32 Bio stock, see the QTTB Stock Forecast page.
Spark’s Take on QTTB Stock
According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses, significant cash burn, and negative equity). Technicals are constructive with strong momentum but appear overbought, and corporate events provide a positive offset via improved runway and strategic focus; valuation remains constrained by negative earnings.
To see Spark’s full report on QTTB stock, click here.
More about Q32 Bio
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody designed to re-regulate adaptive immune function, targeting IL-7 and TSLP pathways implicated in T cell-mediated autoimmune conditions.
Average Trading Volume: 3,136,054
Technical Sentiment Signal: Hold
Current Market Cap: $47.99M
For an in-depth examination of QTTB stock, go to TipRanks’ Overview page.